Abstract: A system and method for determining a response of a tumor following a chemotherapy process includes the use of a magnetic resonance elastography (MRE) driver and a magnetic resonance imaging (MRI) system. The method includes controlling the MRE driver and the MRI system to acquire raw MRE data from the tumor, inverting the raw MRE data to produce an elastogram of the tumor, and determining a response of the tumor to the chemotherapy process from the elastogram.

Abstract: A system and method for determining a response of a tumor following a chemotherapy process includes the use of a magnetic resonance elastography (MRE) driver and a magnetic resonance imaging (MRI) system. The method includes controlling the MRE driver and the MRI system to acquire raw MRE data from the tumor, inverting the raw MRE data to produce an elastogram of the tumor, and determining a response of the tumor to the chemotherapy process from the elastogram.

Abstract: The present invention provides an isolated polynucleotide comprising at least one polymorphic nucleotide sequence, for example, the major alleles of the SNPs described as rs12583006, rs1224141, and rs1248930 and diagnostic assays for detecting the presence of these polymorphism associated with a condition associated with BLyS activity, such as hematological malignancy including B cell malignancies. The diagnostic assays are useful in predicting an individual's likelihood of developing a condition associated with BLyS activity, such as hematological malignancies, and for methods for treating an individual clinically diagnosed with a condition associated with BLyS activity, such as prediction of a patient's likelihood to respond to a specific drug treatment. The invention also provides an array of nucleic acid molecules immobilized on a solid surface, where at least one of the nucleic acid molecules comprises a BLyS polymorphic nucleic acid molecule.

Abstract: The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.

Abstract: The present invention provides an isolated polynucleotide comprising at least one polymorphic nucleotide sequence, for example, at position ?871 from the promoter region of the BLyS gene, and diagnostic assays for detecting the presence of this polymorphism associated with a condition associated with BLyS activity, such as hematological malignancy including B cell malignancies. The diagnostic assays are useful in predicting an individual's likelihood of developing a condition associated with BLyS activity, such as hematological malignancies, and for methods for treating an individual clinically diagnosed with a condition associated with BLyS activity, such as prediction of a patient's likelihood to respond to a specific drug treatment. The invention also provides an array of nucleic acid molecules immobilized on a solid surface, where at least one of the nucleic acid molecules comprises a BLyS polymorphic nucleic acid molecule.

Abstract: The present invention provides an isolated polynucleotide comprising at least one polymorphic nucleotide sequence, for example, the major alleles of the SNPs described as rs12583006, rs1224141, and rs1248930 and diagnostic assays for detecting the presence of these polymorphism associated with a condition associated with BLyS activity, such as hematological malignancy including B cell malignancies. The diagnostic assays are useful in predicting an individual's likelihood of developing a condition associated with BLyS activity, such as hematological malignancies, and for methods for treating an individual clinically diagnosed with a condition associated with BLyS activity, such as prediction of a patient's likelihood to respond to a specific drug treatment. The invention also provides an array of nucleic acid molecules immobilized on a solid surface, where at least one of the nucleic acid molecules comprises a BLyS polymorphic nucleic acid molecule.

Abstract: A system and method for a certificate verifier to make a request to a certificate distribution server for a copy of another entity's digital certificate and to have the certificate distribution center validate it. The certificate distribution center can request the appropriate certificates and validation thereof from a number of certificate authorities or may alternatively obtain copies from a certificate cache and validate the copies against a revocation list server.

Abstract: A system and method of relating a public key to a compact identification string in a digital certificate to enable an entity to construct a certificate chain from a root certificate authority to an end-entity efficiently and further allow a certificate holder to store only its identifier, thus providing privacy protection, and present this in place of a digital certificate for authentication rather than storing and presenting its certificate or a chain of certificates representing the certificate path up to the root certificate authority. In a preferred embodiment, the certificate authority generates unique identifier for each certificate consisting its pseudonym concatenated with the pseudonyms of other sub-certificate authorities in the certificate chain between it and the certificate holder, concatenated with certificate holder's pseudonym. The pseudonyms are generated by the entity known by the pseudonym or the entity certifying a binding between the pseudonym and the entity's public key.

Abstract: A system and method of relating a public key to a compact identification string in a digital certificate to enable an entity to construct a certificate chain from a root certificate authority to an end-entity efficiently and further allow a certificate holder to store only its identifier, thus providing privacy protection, and present this in place of a digital certificate for authentication rather than storing and presenting its certificate or a chain of certificates representing the certificate path up to the root certificate authority. In a preferred embodiment, the certificate authority generates unique identifier for each certificate consisting its pseudonym concatenated with the pseudonyms of other sub-certificate authorities in the certificate chain between it and the certificate holder, concatenated with certificate holder's pseudonym. The pseudonyms are generated by the entity known by the pseudonym or the entity certifying a binding between the pseudonym and the entity's public key.